Lexeo Therapeutics, Inc. Common Stock (LXEO) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LXEO Revenue Growth
LXEO Revenue Analysis (2020–2024)
As of May 8, 2026, Lexeo Therapeutics, Inc. Common Stock (LXEO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, LXEO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.7 million in 2021.
When compared to Healthcare sector peers including KRYS (+25.1% YoY), SGMO (-37.1% YoY), and RARE (+13.3% YoY). Compare LXEO vs KRYS →
LXEO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LXEOCurrent | $0 | - | - | - | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
LXEO Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-105,766,000 | - |
| 2023 | $0 | -100.0% | $0 | - | $-68,513,000 | - |
| 2022 | $654K | -60.5% | $654K | 100.0% | $-60,509,000 | -9252.1% |
| 2021 | $1.7M | +219.6% | $1.7M | 100.0% | $-50,637,000 | -3055.9% |
| 2020 | $518K | - | $518K | 100.0% | $-4,587,788 | -884.9% |
See LXEO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXEO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXEO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXEO — Frequently Asked Questions
Quick answers to the most common questions about buying LXEO stock.
Is LXEO's revenue growth accelerating or slowing?
LXEO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is LXEO's long-term revenue growth rate?
Lexeo Therapeutics, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is LXEO's revenue distributed by segment?
LXEO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.